Showing results (1401-1410 of 1,955) with videos related to
Sort By:
Pageof 196
Bioorganic & Medicinal Chemistry Letters|May 7, 1999
N-hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenaseP J Connolly, S K Wetter, K N Beers, et al.Bioorganic & Medicinal Chemistry Letters|April 11, 2013
Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1)Timothy M Chapman, Simon A Osborne, Nathalie Bouloc, et al.Open Heart|October 27, 2018
Characterisation of circulating biomarkers before and after cardiac resynchronisation therapy and their role in predicting CRT response: the COVERT-HF studyChristopher J McAloon, Temo Barwari, Jimiao Hu, et al.Bone Marrow Transplantation|November 2, 2004
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rateM A Gertz, M Q Lacy, A Dispenzieri, et al.Journal for Immunotherapy of Cancer|December 28, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphomaSattva S Neelapu, Sherry Adkins, Stephen M Ansell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2012
Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemiaLaura A Vitale, Li-Zhen He, Lawrence J Thomas, et al.Leukemia & Lymphoma|July 7, 2007
Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasoneLijo Simpson, Stephen M Ansell, Joseph P Colgan, et al.Blood|January 5, 2002
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphomaStephen M Ansell, Thomas E Witzig, Paul J Kurtin, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 16, 2002
Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemiaJames R Cerhan, Celine M Vachon, Thomas M Habermann, et al.Blood|December 24, 2014
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphomaAjay K Gopal, Robert Chen, Scott E Smith, et al.Pageof 196